MDxHealth, Inc. - צמיחת מכירות משנה לשנה ב-12 החודשים האחרונים MDXH

The Belgian developer MDxHealth SA (MDXH) helps patients avoid repeat prostate biopsies. The year-over-year sales trajectory over the trailing four quarters visualizes this demand, with the latest value recorded as 3.60. High motivation among in-house biologists strengthens diagnostic quality, while the centralization of laboratories in the US creates operational leverage, significantly increasing the business's net margins.
פילוחי נתונים אנליטיים מרוכזים עבור MDxHealth (MDXH)

For MDxHealth SA (MDXH), this indicator serves as a tool to assess the scalability of the diagnostic business based on the medical community's recognition of tests and insurance reimbursements. By analyzing the LTM sales growth rate, calculated as the percentage change in revenue over a rolling 12-month period, investors can determine the stability of the fundamental trend, distinguishing systemic market share expansion from random short-term spikes.